參附注射液治療感染性休克的臨床療效分析

曹健華

[摘要] 目的 探討參附注射液治療感染性休克的臨床療效。 方法 回顧性分析該院2017年11月—2019年2月收治的56例感染性休克患者的臨床資料。患者隨機分成治療組和對照組，其中治療組30例，除西醫常規治療外加用參附注射液，對照組26例僅用西醫常規治療，不加用參附注射液。觀察并比較兩組的平均動脈壓（MAP）、中心靜脈血氧飽和度（ScVO2）、心率（HR）、乳酸（Lac）、ICU住院時間、病死率以及多器官功能不全發生率。 結果 治療24 h后治療組與對照組平均動脈壓（MAP）分別為（72±9.2）mmHg、（66±8.4） mmHg，差異有統計學意義（P=0.014<0.05）;中心靜脈血氧飽和度（ScVO2）分別為（86±14.3）%、（75±13.6）%，差異有統計學意義（P=0.020<0.05）;心率（HR）分別為（105±10.2）次、（113±12.4）次，差異有統計學意義（P=0.011<0.05）;乳酸（Lac）分別為（3.6±0.68）mmol/L、（4.2±0.81）mmol/L，差異有統計學意義（P=0.004<0.05）。治療組與對照組ICU 住院時間分別為（8.3±2.7）d、（10.1±3.5）d，治療組比對照組短，差異有統計學意義（P=0.034<0.05）。兩組死亡率分別為20.0%、23.1%，差異無統計學意義（P=0.780>0.05）。兩組多器官功能不全發生率分別為16.7%、42.3%，治療組低于對照組，差異有統計學意義（P=0.034<0.05）。 結論 參附注射液可改善感染性休克患者的微循環，可以提高感染性休克的治療效果，縮短住院時間，具有一定的臨床應用價值。

[關鍵詞] 參附注射液;感染性休克;臨床療效

[中圖分類號] R278? ? ? ? ? [文獻標識碼] A? ? ? ? ? [文章編號] 1674-0742（2019）11（b）-0121-03

[Abstract] Objective To investigate the clinical efficacy of Shenfu injection in the treatment of septic shock. Methods The clinical data of 56 patients with septic shock admitted to the hospital from November 2017 to February 2019 were retrospectively analyzed. The patients were randomly divided into the treatment group and the control group， including 30 patients in the treatment group， except for the conventional treatment of western medicine plus Shenfu injection， and 26 patients in the control group were treated with only Western medicine， and Shenfu injection was not used. Mean arterial pressure （MAP）， central venous oxygen saturation （ScVO2）， heart rate （HR）， lactic acid （Lac）， ICU hospitalization， mortality， and multiple organ dysfunction were observed and compared between the two groups. Results After 24 hours of treatment， the mean arterial pressure （MAP） of the treatment group and the control group were（72±9.2）mmHg and（ 66±8.4 ）mmHg， respectively. The difference was statistically significant （P=0.014<0.05）; central venous oxygen saturation （ScVO2） was （86±14.3）% and （75±13.6）%， respectively， with statistically significant differences （P=0.020<0.05）. Heart rate （HR） was （105±10.2 ）times and （113±12.4） times， respectively， and the difference was statistically significant （P=0.011<0.05）; Lac was （3.6±0.68）mmol/L and （4.2±0.81）mmol/L， respectively， with statistically significant differences （P=0.004<0.05）. The hospital stay in the ICU of the treatment group and the control group were （8.3±2.7）d and （10.1±3.5）d， respectively. The treatment group was shorter than the control group， and the difference was statistically significant （P=0.034<0.05）. The mortality rate of the two groups was 20.0% and 23.1%， respectively， and the difference was not statistically significant （P=0.780>0.05）. The incidence of multiple organ dysfunction in the two groups was 16.7% and 42.3%， respectively. The treatment group was lower than the control group， and the difference was statistically significant （P=0.034<0.05）. Conclusion Shenfu injection can improve the microcirculation of patients with septic shock， improve the therapeutic effect of septic shock， shorten the hospital stay， and have certain clinical application value.